Soligenix Inc SEC Filings

Welcome to our dedicated page for Soligenix SEC filings (Ticker: SNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Soligenix, Inc. (SNGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its 10-K and 10-Q reports, 8-K current reports and registration statements such as Form S-1. Soligenix describes itself in these documents as a Delaware-incorporated, late-stage biopharmaceutical company listed on The Nasdaq Capital Market, focused on rare-disease therapeutics and biodefense-oriented vaccines through its Specialized BioTherapeutics and Public Health Solutions segments.

For this issuer, Form 10-K and Form 10-Q are central for understanding segment results, research and development spending, risk factors and details on programs like HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, dusquetide-based candidates SGX942 and SGX945, and vaccine initiatives such as RiVax®, filovirus vaccines and CiVax™ leveraging the ThermoVax® platform. These periodic reports also describe government grant and contract funding from agencies including NIAID, DTRA and BARDA that support the Public Health Solutions segment.

Form 8-K current reports are particularly relevant for SNGX because they capture material events such as clinical milestones, FDA orphan drug designations, equity offerings and Nasdaq listing status updates. For example, 8-K filings in 2025 document an orphan drug designation for dusquetide in Behçet's Disease, a Nasdaq notice regarding stockholders’ equity compliance and a subsequent notice of regained compliance, the approval of a 2025 equity incentive plan, and the closing of a public offering that extended the company’s cash runway.

On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as new financing terms, changes in capital structure, or updates to clinical and regulatory strategy. Users can also track insider transaction reports on Form 4, along with registration statements like Form S-1 related to public offerings and warrant issuances, to better understand dilution, capital-raising activities and governance matters for Soligenix.